Releasing the Brake on Oncolytic Viral Therapy

Clare Y Slaney; Phillip K Darcy

doi:10.1158/1078-0432.CCR-15-1769

Releasing the Brake on Oncolytic Viral Therapy

Clin Cancer Res. 2015 Dec 15;21(24):5417-9. doi: 10.1158/1078-0432.CCR-15-1769. Epub 2015 Sep 16.

Authors

Clare Y Slaney¹, Phillip K Darcy²

Affiliations

¹ Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia. [email protected] [email protected].
² Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia. Department of Pathology, University of Melbourne, Parkville, Australia. Department of Immunology, Monash University, Clayton, Victoria, Australia. [email protected] [email protected].

PMID: 26378034
DOI: 10.1158/1078-0432.CCR-15-1769

Abstract

Oncolytic virus that selectively targets and eradicates tumor cells and immune checkpoint blockade that unleashes host antitumor immune responses show synergistic effects against cancer. This combination holds great promise for future treatment of a broad range of cancers in patients. Clin Cancer Res; 21(24); 5417-9. ©2015 AACR.See related article by Rojas et al., p. 5543.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Neoplasms / therapy
Oncolytic Virotherapy*
Oncolytic Viruses
Virus Replication*